胃食管癌免疫检查点抑制剂:解析异质性以理解一线与辅助治疗角色
本文综述2020年四项关键试验(CheckMate 649、ATTRACTION-4、KEYNOTE-590、CheckMate 577),确立抗PD-1治疗在部分胃食管腺癌(GEA)和食管鳞癌(ESCC)一线晚期及辅助治疗的新标准。CheckMate 649中化疗联合纳武利尤单抗在CPS≥5的GEA中显著改善总生存,而ATTRACTION-4未见相似总生存获益。KEYNOTE-590在CPS≥10的ESCC中显著改善生存,CheckMate 577证实高危切除后辅助纳武利尤单抗改善无病生存。
要点
- CPS≥5的GEA一线化疗联合纳武利尤单抗显著改善总生存。
- CPS≥10的ESCC一线化疗联合帕博利珠单抗显著改善生存。
- 高危切除后GEA/ESCC辅助纳武利尤单抗改善无病生存。
核心结论
- 免疫检查点抑制剂已成为部分GEA和ESCC一线及辅助治疗标准,生物标志物标准化对选择获益患者至关重要。
研究设计与样本
- 综述分析了CheckMate 649、ATTRACTION-4、KEYNOTE-590和CheckMate 577四项试验结果,并结合现行标准与历史试验进行讨论。
主要发现
- CheckMate 649中,奥沙利铂-氟嘧啶化疗联合纳武利尤单抗在CPS≥5的GEA患者中提供有临床意义且统计学显著的总生存改善。
- ATTRACTION-4中无进展生存明显改善,但未观察到相似的总生存获益。
- KEYNOTE-590中,顺铂-氟嘧啶化疗联合帕博利珠单抗在CPS≥10的ESCC患者中显著改善生存,未选择ESCC中获益较不明确。
- CheckMate 577证实高危切除后GEA和ESCC接受辅助纳武利尤单抗可改善无病生存。
关键数值与推荐
- CheckMate 649:CPS≥5的GEA患者,化疗联合纳武利尤单抗对比化疗,总生存改善有统计学显著差异。
- KEYNOTE-590:CPS≥10的ESCC患者,化疗联合帕博利珠单抗对比化疗,生存显著改善。
- CheckMate 577:高危切除后GEA和ESCC,辅助纳武利尤单抗对比安慰剂,无病生存改善。
临床怎么用
- 对CPS≥5的GEA和CPS≥10的ESCC一线治疗可考虑化疗联合抗PD-1治疗。
- 高危切除后GEA和ESCC可考虑辅助纳武利尤单抗。
局限性
- ATTRACTION-4未显示总生存获益,需进一步解释。
- 免疫逃逸肿瘤的新联合方案仍在开发中,需全球试验验证。
- 生物标志物标准化尚未解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for >1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of <1 year. Anti- programmed cell death protein 1 (anti-PD-1) monotherapy has demonstrated modest efficacy in previously treated GEA and ESCC. In 2020, four pivotal trials have established anti-PD-1 therapy as a new standard of care for selected GEA and ESCC patients as first-line advanced and adjuvant therapy. In this review, we discuss the recent results of the CheckMate 649, ATTRACTION-4, KEYNOTE-590 and CheckMate 577 trials. We consider these results in the context of current standards of care and historical trials of immune checkpoint blockade in GEA and ESCC. We explore biomarker selection for anti-PD-1 therapy and appraise the future of combination therapies. In CheckMate 649, treatment with oxaliplatin-fluoropyrimidine chemotherapy plus nivolumab in patients with combined positive score ≥5 GEA tumors provided a clinically meaningful and statistically significant improvement in overall survival. The ATTRACTION-4 trial did not see a similar overall survival benefit, despite a clear improvement in progression-free survival. We review potential explanations for this result. KEYNOTE-590 showed profoundly improved survival when pembrolizumab was added to cisplatin-fluoropyrimidine chemotherapy in ESCC patients with combined positive score ≥10 tumors; this benefit was less convincing in unselected ESCC. Finally, CheckMate 577 provides proof-of-concept for the improvement in disease-free survival with adjuvant nivolumab in high-risk resected GEA and ESCC following trimodality therapy. Immune checkpoint blockade has come of age in GEA and ESCC, and will now be integrated into first-line and earlier lines of therapy, providing benefit for a larger proportion of patients. Biomarker standardization will be critical to select the patients most likely to benefit from treatment. For patients with immune evasive tumors, novel combinations under development show promise; however, global trials are needed.
引用
- Smyth EC, Gambardella V, Cervantes A, et al. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021. PMID: 33609722. doi:10.1016/j.annonc.2021.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。